The Effect of Branched Chain Amino Acid to the Perioperative Nutritional Status: In Patients with Cirrhosis Undergoing Liver Resection and Patients Awaiting Liver Transplantation.

The Effect of Branched Chain Amino Acid to the Perioperative Nutritional Status: In Patients with Cirrhosis Undergoing Liver Resection and Patients Awaiting Liver Transplantation. - The effect of the neutritional support in perioperative care of hepatic resection and Liver transplantation.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009154

Enrollment

130

Registered

2012-10-22

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patient with cirrhosis undergoing liver resection.(hepatocellular carcinoma, bile duct cancer, metastasis of colorectal cancer, and other malignant tumors) The patient awaiting for liver transolantation.(Liver cirrhosis, Hepatocellular carcinoma, Fulminant hepatic failure, Primary billiary cirrosis, Primary screlosing cholangitis, Autoimune hepatitis, and other metabolic liver diseases.)

Interventions

Patients assigned for intervention group take Branched-chain amino acid formula as late-evening snack for 2 weeks preoperatively in hepatic resction,and for 4 weeks in liver transplantation,respectiv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients assigned to this study must be compatible with all criteria listed below. 1)Patients awaiting liver transplantation or patients with cirrhosis( ICG R15 > 15%) undergoing hepatic resection. 2)Patients undergoing hepatic resection must be over the age 20,and under the age of 80. Patients awaiting liver transplantation must be over the age of 20, and under the age of 65. 3)Sufficient understanding of the study and voluntary consent for the study in writting.

Exclusion criteria

Exclusion criteria: 1) Patients who have already taken Branched -chain amino acid formula before. 2) Patients who have a past history of milk allergy. 3) Patients who have or be suspected of having glycometabolism dysfunction due to severe diabetes mellitus or bolus administration of steroidal drugs. 4)Patients who are in the first trimester of pregnancy or wish to become pregnant. 5)Patients with amino-acid metabolism dysfunction. 6) Patients with fulminant hepatitis. 7) Patients who are considered medically inappropriate for registration.

Design outcomes

Primary

Measure	Time frame
Body cell mass	—

Secondary

Measure	Time frame
Infectious complications, Other complications, Neutritional indexes, Length of hospital stay, Recurrence-free survival time, Overall survival time.	—

Countries

Japan

Contacts

Public ContactNagata Rihito

The University of Tokyo epertment of Hepato-Billiary-Pancreatic Surgery, Guraduate School of Medicine

rnagata-tky@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026